Les maladies neurologiques augmentent-elles le risque ?
Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs.
Maladies neurologiquesSensibilitéRisque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques voltage-dépendants : Questions médicales les plus fréquentes",
"headline": "Bloqueurs de canaux sodiques voltage-dépendants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bloqueurs de canaux sodiques voltage-dépendants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-25",
"dateModified": "2025-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Bloqueurs de canaux sodiques",
"url": "https://questionsmedicales.fr/mesh/D026941",
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques",
"code": {
"@type": "MedicalCode",
"code": "D026941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D27.505.954.411.720"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"alternateName": "Voltage-Gated Sodium Channel Blockers",
"code": {
"@type": "MedicalCode",
"code": "D061567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "William A Catterall",
"url": "https://questionsmedicales.fr/author/William%20A%20Catterall",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA 98195, USA. Electronic address: wcatt@uw.edu."
}
},
{
"@type": "Person",
"name": "Piyasuda Pukkanasut",
"url": "https://questionsmedicales.fr/author/Piyasuda%20Pukkanasut",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Sadanandan E Velu",
"url": "https://questionsmedicales.fr/author/Sadanandan%20E%20Velu",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Alabama at Birmingham, Birmingham, AL 35294, USA."
}
},
{
"@type": "Person",
"name": "Tamer M Gamal El-Din",
"url": "https://questionsmedicales.fr/author/Tamer%20M%20Gamal%20El-Din",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, University of Washington, Seattle, WA, United States."
}
},
{
"@type": "Person",
"name": "Christopher L-H Huang",
"url": "https://questionsmedicales.fr/author/Christopher%20L-H%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Hopkins Building, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QW, UK."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/36068430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40264-022-01216-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferric Carboxymaltose in Heart Failure with Iron Deficiency.",
"datePublished": "2023-08-26",
"url": "https://questionsmedicales.fr/article/37632463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1056/NEJMoa2304968"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ferric Pyrophosphate Forms Soluble Iron Coordination Complexes with Zinc Compounds and Solubilizing Agents in Extruded Rice and Predicts Increased Iron Solubility and Bioavailability in Young Women.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36931746",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.tjnut.2022.12.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "A Systematic Review, Meta-Analysis, and Indirect Comparison of Blindly Adjudicated Cardiovascular Event Incidence with Ferric Derisomaltose, Ferric Carboxymaltose, and Iron Sucrose.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35947351",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12325-022-02242-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.",
"datePublished": "2022-07-06",
"url": "https://questionsmedicales.fr/article/35790696",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12185-022-03401-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Actions chimiques et utilisations",
"item": "https://questionsmedicales.fr/mesh/D020164"
},
{
"@type": "ListItem",
"position": 3,
"name": "Actions pharmacologiques",
"item": "https://questionsmedicales.fr/mesh/D020228"
},
{
"@type": "ListItem",
"position": 4,
"name": "Utilisations thérapeutiques",
"item": "https://questionsmedicales.fr/mesh/D045506"
},
{
"@type": "ListItem",
"position": 5,
"name": "Agents cardiovasculaires",
"item": "https://questionsmedicales.fr/mesh/D002317"
},
{
"@type": "ListItem",
"position": 6,
"name": "Bloqueurs de canaux sodiques",
"item": "https://questionsmedicales.fr/mesh/D026941"
},
{
"@type": "ListItem",
"position": 7,
"name": "Bloqueurs de canaux sodiques voltage-dépendants",
"item": "https://questionsmedicales.fr/mesh/D061567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bloqueurs de canaux sodiques voltage-dépendants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?\nQuels tests sont utilisés pour évaluer l'effet des bloqueurs ?\nQuels symptômes indiquent une surdose de bloqueurs ?\nComment différencier les types de bloqueurs de canaux ?\nQuels antécédents médicaux sont pertinents pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Ferric+Compounds#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les symptômes d'une intoxication aiguë ?\nComment se manifestent les effets secondaires des bloqueurs ?\nQuels signes indiquent une réaction allergique ?\nLes bloqueurs affectent-ils la respiration ?\nQuels symptômes neurologiques peuvent apparaître ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Ferric+Compounds#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Comment prévenir les effets indésirables des bloqueurs ?\nQuelles précautions doivent être prises avant la prescription ?\nLes patients doivent-ils être informés des risques ?\nComment éviter les interactions médicamenteuses ?\nQuelles sont les recommandations pour les patients à risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Ferric+Compounds#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quel est le traitement d'une surdose de bloqueurs ?\nComment gérer les effets secondaires des bloqueurs ?\nQuels médicaments peuvent interagir avec les bloqueurs ?\nLes bloqueurs sont-ils utilisés en anesthésie ?\nQuelle est l'importance de la surveillance pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Ferric+Compounds#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quelles complications peuvent survenir avec les bloqueurs ?\nComment les complications sont-elles gérées ?\nLes complications sont-elles fréquentes ?\nQuels facteurs augmentent le risque de complications ?\nLes complications peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Ferric+Compounds#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bloqueurs de canaux sodiques voltage-dépendants",
"description": "Quels sont les principaux facteurs de risque ?\nComment l'âge influence-t-il le risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'usage de drogues illicites est-il un facteur de risque ?\nLes maladies neurologiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D061567?mesh_terms=Ferric+Compounds#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux bloqueurs de canaux sodiques ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un diagnostic repose sur l'historique médical, les symptômes cliniques et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'effet des bloqueurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des électrocardiogrammes et des tests de conduction nerveuse peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une surdose de bloqueurs ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, une arythmie cardiaque et une dépression respiratoire peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment différencier les types de bloqueurs de canaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse des effets cliniques et des mécanismes d'action aide à les différencier."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux sont pertinents pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques ou neurologiques sont cruciaux pour le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une intoxication aiguë ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des nausées, des troubles de la vision et des convulsions."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les effets secondaires des bloqueurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des étourdissements, des maux de tête et des troubles de la coordination."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, des démangeaisons et un gonflement peuvent signaler une allergie."
}
},
{
"@type": "Question",
"name": "Les bloqueurs affectent-ils la respiration ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent entraîner une dépression respiratoire dans les cas graves."
}
},
{
"@type": "Question",
"name": "Quels symptômes neurologiques peuvent apparaître ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des convulsions, des troubles de la conscience et des paralysies peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment prévenir les effets indésirables des bloqueurs ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une prescription appropriée et une éducation du patient sont essentielles pour prévenir les effets indésirables."
}
},
{
"@type": "Question",
"name": "Quelles précautions doivent être prises avant la prescription ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évaluer les antécédents médicaux et les allergies du patient est crucial avant la prescription."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils être informés des risques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, informer les patients des risques et des signes d'intoxication est essentiel."
}
},
{
"@type": "Question",
"name": "Comment éviter les interactions médicamenteuses ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen minutieux des médicaments prescrits et des antécédents est nécessaire pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les patients à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients à risque doivent être suivis de près et éduqués sur les signes d'alerte."
}
},
{
"@type": "Question",
"name": "Quel est le traitement d'une surdose de bloqueurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des soins de soutien, l'administration de charbon actif et des antidotes si disponibles."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des bloqueurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique l'ajustement de la dose ou le changement de médicament selon les symptômes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent interagir avec les bloqueurs ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les antidépresseurs et les anesthésiques peuvent interagir."
}
},
{
"@type": "Question",
"name": "Les bloqueurs sont-ils utilisés en anesthésie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains bloqueurs de canaux sodiques sont utilisés pour induire une anesthésie locale."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance pendant le traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter les effets indésirables et ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les bloqueurs ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des arythmies, des convulsions et des défaillances respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une intervention rapide et un traitement symptomatique."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, surtout en cas de surdose ou d'interactions."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge avancé, les maladies cardiaques et l'utilisation concomitante d'autres médicaments augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance attentive et une éducation adéquate peuvent aider à prévenir certaines complications."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de maladies cardiaques, l'âge et l'utilisation d'autres médicaments sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées ont un risque accru de complications en raison de la polypharmacie et de la fragilité."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies cardiaques ou neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'usage de drogues illicites est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage de certaines drogues peut interagir avec les bloqueurs et augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les maladies neurologiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients ayant des maladies neurologiques peuvent être plus sensibles aux effets des bloqueurs."
}
}
]
}
]
}
The intravenous iron formulations ferric carboxymaltose (FCM) and ferric derisomaltose (FDI) offer the possibility of administering a large amount of iron in one infusion. This results in faster corre...
Ferric carboxymaltose therapy reduces symptoms and improves quality of life in patients who have heart failure with a reduced ejection fraction and iron deficiency. Additional evidence about the effec...
In this double-blind, randomized trial, we assigned ambulatory patients with heart failure, a left ventricular ejection fraction of 40% or less, and iron deficiency, in a 1:1 ratio, to receive intrave...
We enrolled 3065 patients, of whom 1532 were randomly assigned to the ferric carboxymaltose group and 1533 to the placebo group. Death by month 12 occurred in 131 patients (8.6%) in the ferric carboxy...
Among ambulatory patients who had heart failure with a reduced ejection fraction and iron deficiency, there was no apparent difference between ferric carboxymaltose and placebo with respect to the hie...
Co-extrusion of ferric pyrophosphate (FePP) with solubilizers, citric acid/trisodium citrate (CA/TSC), or ethylenediaminetetraacetic acid (EDTA) sharply increases iron absorption. Whether this can pro...
Our objectives were to 1) investigate the ligand coordination of iron, zinc, and solubilizers in extruded rice and test associations with iron solubility and absorption, 2) assess whether co-extrusion...
We produced labeled...
The addition of zinc and solubilizers created new iron coordination complexes of Fe(III) species with a weak ligand field at a high-spin state that correlated with solubility (r...
Rice extrusion of FePP with solubilizers resulted in bioavailable iron coordination complexes. In the case of FePP + CA/TSC, PA exerted similar inhibition of FIA as with FeSO...
Intravenous (IV) iron is the preferred treatment for patients with iron deficiency anemia (IDA) who require rapid replenishment of iron stores or in whom oral iron is not tolerated or effective. Data ...
RCTs reporting the incidence of blindly adjudicated cardiovascular events in IDA patients treated with IV iron were identified by systematic literature review (SLR). Pairwise random effects meta-analy...
The SLR retrieved 694 unique articles, of which four were RCTs reporting the incidence of the composite cardiovascular endpoint; two studies comparing FCM (N = 1529) with IS (N = 1505), and two studie...
Pooling data from four large-scale RCTs suggested that FDI was associated with significantly lower incidence of cardiovascular adverse events compared to both FCM and IS....
A multicenter, randomized, open-label, phase III study was conducted to compare the efficacy and safety of intravenous ferric derisomaltose (FDI) versus saccharated ferric oxide (SFO) in Japanese pati...
Bioremediation provides an environmentally sound solution for hydrocarbon removal. Although bioremediation under anoxic conditions is slow, it can be coupled with methanogenesis and is suitable for en...
The randomized IronIC trial evaluated the effect of intravenous ferric derisomaltose on physical capacity in iron-deficient, maintenance heart transplant (HTx) recipients. Iron deficiency was defined ...
We assessed key governors of iron homeostasis, such as hepcidin, soluble transferrin receptor (sTfR), and interleukin-6 (IL-6). We also measured growth factors and inflammatory markers with relevance ...
Hepcidin did not differ between HTx recipients and controls, even though markers of inflammation were modestly elevated. However, HTx recipients with ferritin <30 μg/L or sTfR above the reference rang...
HTx recipients with iron deficiency as defined in heart failure do not have elevated hepcidin levels, although inflammatory markers are modestly increased. The high ferritin cut-offs used in heart fai...
In this study, a fast, reproducible and simple-to-apply a new potentiometric determination method was developed for the evaluation of iron (III) reducing power (FRAP), one of the antioxidant capacity ...
The heterogeneous Fenton-like reaction (HeFR) has always been a research focus for environmental applications. However, it has long been difficult to reach a consensus on the reaction mechanism becaus...
Cardiovascular diseases are a leading cause of mortality and morbidity worldwide. Aberrant thrombosis is a common feature of systemic conditions like diabetes and obesity, and chronic inflammatory dis...